Precision medicine solutions company CareDx Inc (NASDAQ: CDNA), known as The Transplant Company, reported on Tuesday that it presents its latest cardiothoracic advancements at the ISHLT 44th Annual Meeting & Scientific Sessions in Prague, Czech Republic, from 10 to 13 April 2024.
The presentations feature CareDx's cardiothoracic portfolio, including AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung and AiCAV (in development), showcasing real-world applications in over 25 presentations.
Experts discuss the use of CareDx's solutions in clinical decision-making and managing real-world scenarios in two CareDx sponsored symposia, highlighting innovations in heart and lung transplantation care.
Headquartered in Brisbane, California, CareDx is focused on developing high-value healthcare solutions for transplant patients and caregivers, offering testing services, products and digital healthcare solutions.
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
BerGenBio partners with Tempus to advance lung cancer drug
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults